The Department of Health – Abu Dhabi (DoH), the regulator of healthcare in the emirate, has signed a strategic collaboration pact with the US pharma major Johnson & Johnson to support the emirate’s vision in developing a regional hub for clinical research and data generation.
The new strategic collaboration, signed with Johnson & Johnson Middle East FZ-LLC, seeks to bring innovative treatments and breakthrough solutions to the UAE and the MENA region, as well as exchange knowledge and experiences across the healthcare sector.
The Abu Dhabi health department and the Middle East arm of the US company will explore key potential areas of interest to develop short and long-term projects in the generation of data and real-world evidence (RWE).
The Declaration of Collaboration was signed by Dr. Asma Al Mannaei, executive director, research and innovation centre at DoH, and Jamie Phares, managing director of Janssen GCC, a Johnson and Johnson company.
The strategic pact with Johnson and Johnson, signed during the BIO International Convention 2022 held in San Diego, California on June 13-16, is line with Abu Dhabi’s initiatives to seek lead research groups supported by global partners to establish the strength and sustainability of the healthcare sector as well as provide quality care to patients in the emirate.
An Abu Dhabi delegation is participating at the BIO International Convention 2022 to showcase the domestic growth and economic development of the emirate’s biotechnology industry.
Headed by Abdullah bin Mohammed Al Hamed, Chairman of DoH, the Abu Dhabi delegation is visiting the US to explore prospects of joint collaboration within the framework of healthcare at large and life science in specific.
Abu Dhabi Dr. Asma Al Mannaei, executive director, Research and Innovation Centre at the Department of Health – Abu Dhabi (DoH), said, “Our collaborations with leading healthcare companies echo Abu Dhabi’s ongoing efforts to position itself as a leading life science destination as well as an incubator for innovation.
“Through our collaboration with Johnson Middle East, FZ LLC, we aim to further improve the resilience and sustainability of the healthcare sector as well as provide quality care to patients in Abu Dhabi and worldwide.”
Powered by a solid infrastructure, and an advanced healthcare ecosystem, collaboration opportunities across the biopharmaceutical and healthcare value chain in Abu Dhabi continue to emerge because of the sector’s robust growth potential.
Follow us on
